CORDIS
EU research results

CORDIS

English EN

A training network for the chemical site-selective modification of proteins: Preparation of the next-generation of therapeutic chemically-defined protein conjugates

Objective

ProteinConjugates is an inter- and multi-disciplinary network for the education of talented young scientists who will learn how to rationally design and construct the next generation of chemically-defined and innovative protein drug-conjugates for the targeted treatment of serious conditions such as cancer or rheumatoid arthritis. A complementary interaction between academy and pharmaceutical industry is at the centre of such a network, which involves 8 academic groups and 1 SME partner as beneficiaries, and 2 leading European industrial partner organizations that will host secondments while providing training. The combined expertise of the beneficiaries and industrial partners in synthesis of complex molecules, molecular dynamics, supramolecular self-assembly, site-selective chemical protein modification, protein/antibody engineering, cancer therapeutics and drug development together with the experience in project management and training of PhDs and Postdocs of the PIs, will create a multidisciplinary environment where 10 young researchers can foster their knowledge and skills while developing the most innovative ideas in the emerging fields of chemical site-selective protein modification and protein biotherapeutics. Exposure to the highly dynamic and multidisciplinary ProteinConjugates environment will contribute to the education of the next generation of leaders in the emerging field of protein biotherapeutics, a key area of research and drug development for Europe's competitiveness.

Coordinator

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Address

Avenida Prof Egas Moniz
1649 028 Lisboa

Portugal

Activity type

Research Organisations

EU Contribution

€ 741 939,48

Participants (8)

Sort alphabetically

Sort by EU Contribution

Expand all

Faculdade de Farmácia da Universidade de Lisboa

Portugal

EU Contribution

€ 238 356,36

UNIVERSITY COLLEGE LONDON

United Kingdom

EU Contribution

€ 273 287,88

UNIVERSITAET ULM

Germany

UNIVERSIDAD DE LA RIOJA

Spain

EU Contribution

€ 247 872,96

THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE

United Kingdom

EU Contribution

€ 273 287,88

INSTITUT CURIE

France

EU Contribution

€ 262 875,60

UNIVERSITAT WIEN

Austria

EU Contribution

€ 255 934,08

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV

Germany

EU Contribution

€ 249 216,48

Partners (2)

Sort alphabetically

Expand all

PHARMAMAR, S.A.

HOVIONE FARMACIENCIA SA

Project information

Grant agreement ID: 675007

Status

Ongoing project

  • Start date

    1 November 2015

  • End date

    31 October 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 542 771,03

  • EU contribution

    € 2 542 770,72

Coordinated by:

INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES

Portugal